SURYAPHARM

��Members of the Exchange are hereby notified that in terms of Regulation 22(6) of the Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009, Section 21A of the Securities Contract (Regulations) Act, 1956, Rule 21(2) b of Securities Contract (Regulations) Rules, 1957 , it has been decided to delist (withdraw the admission to dealings in) equity shares of the Surya Pharmaceutical Limited w.e.f. May 30, 2018 as per Chapter V of SEBI (Delisting of Equity Shares) Regulations, 2009.

The Exchange has sought clarification from the Company with respect to news item captioned-"CBI Files Case Against Three Directors In Rs. 621-Crore Fraud Involving Punjab And Sindh Bank" In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company

Members of the Exchange are hereby informed that the Exchange on February 28, 2018 has issued public notice in the newspaper for�� proposed compulsory delisting of equity shares of the company, in term of Regulation 22 (3) of SEBI (Delisting of Equity shares) Regulation, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/common/CorporateAnnouncements).

Surya Pharmaceutical Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 31-Dec-2014.

Surya Pharmaceutical Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Sep-2014.

Surya Pharmaceutical Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Jun-2014.

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors, in its meeting held on February 3, 2015 have approved and taken on record the Report of Statutory Auditors of the Company on the financial statements of the Company as on and for the year ended March 31, 2014.

Surya Pharmaceutical Limited has informed the Exchange that the financial statements of the Company were approved by the Board of Directors of the Company in the meeting held on November 01, 2014. The aforesaid financial statements were submitted to the Statutory Auditors for their signatures and issuing report of the Auditors thereon. In the wake of certain developments, the Statutory Auditors sought further clarifications and because of it, the Report of Auditors is likely to take some more time. The Company in anticipation that the Auditors will be issuing the Report in due time, intimated

Surya Pharmaceutical Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company shall remain closed from November 27, 2014 to November 29, 2014 (both days inclusive) for the purpose of Annual General Meeting of the Company to be held on November 29, 2014.

Surya Pharmaceutical Limited has submitted to the exchange the standalone financial results for the period ended 31-Mar-2014.

Surya Pharmaceutical Limited has informed the Exchange that the address of Corporate Office of the Company has been shifted from SCO 164-165, Sector 9-C, Madhya Marg, Chandigarh-160009 to SCO 141-143, Sector 43-B, Chandigarh- 160022.

Members of the Exchange are hereby informed that the securities of Surya Pharmaceutical Limited shall be transferred to BZ series with effect from September 24, 2014 due to non-compliances of the Clause 41 of the Listing Agreement for two consecutive quarters i.e. March 2014 and June 2014

Ess Ess Exim Private Ltd has submitted to the Exchange vide letter dated July 31, 2014 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Surya Pharmaceutical Limited had informed the Exchange regarding meeting of the Board of Directors of the Company scheduled to be held on May 30, 2014 to consider and approve Audited Financial Results i.e. Balance Sheet, Profit & Loss Account, Schedules and Notes thereon for the year ended March 31, 2014 of the Company. The Company has now inform the Exchange that the said meeting has been adjourned for the want of quorum as two of the three Directors of the Company, i.e. Mr. Rajiv Goyal and Mrs. Alka Goyal are out of India and were not able to attend the said meeting.

Surya Pharmaceutical Limited has submitted to the exchange the standalone financial results for the period ended 31-dec-2013.

Surya Pharmaceutical Limited has submitted to the exchange the standalone financial results for the period ended 30-Sep-2013.

Surya Pharmaceutical Limited has submitted to the Exchange a copy of the Proceedings of the Annual General Meeting of the Company held on September 30, 2013.

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on October 10, 2013, have appointed Mr. Jasvinder Singh as Independent Additional Director of the Company.

Surya Pharmaceutical Limited has submitted to the Exchange the Standalone Financial Results for the period ended June 30,2013.

Surya Pharmaceutical Limited has informed the Exchange that the Company has fixed Book Closure from September 28, 2013 to September 30, 2013 for the purpose of Annual General Meeting to be held on September 30, 2013.

Surya Pharmaceutical Limited has informed the Exchange regarding outcome of the Board Meeting held on August 14, 2013.

Surya Pharmaceutical Limited has informed the Exchange that as per the audited Balance Sheet of the Company, as considered and approved by the Board of Directors of the Company in its meeting held on the July 20, 2013, the net worth of the Company stands completely eroded. The Company has, in terms of the provisions of the Sick Industrial Companies (Special Provisions) Act, 1985 (SICA), filed a Reference with the Board for Industrial and Financial Reconstruction (BIFR) for being declared a "sick Company" as per the provisions of SICA.

Mr. Dharam Pal Singhal, an Independent Director of the Company, resigned from the said office on June 15, 2013. The resignation of Mr. Dharam Pal Singhal was consequent to the resignations of Mr. Shiv Kumar Yadav (Independent Director) with effect from May 25, 2013 and Mr. Subhash Chander Marwaha (Nominee Director of SBI) with effect from May 29, 2013.As a result of the resignation of Mr. Dharam Pal Singhal, the total strength of the Board of Directors of the Company has reduced to two, which is less than the minimum number of Directors statutorily required for a public limited Company.The Boa

Surya Pharmaceutical Limited has informed the Exchange that consequent to the resignation of Mr. Bharat Bhushan Jain from the post of Chief Financial Officer & Company Secretary cum Compliance Officer of the Company with effect from May 28, 2013, the Company is in the process of appointing Company Secretary under the provisions of section 383A of the Companies Act, 1956, Till the time a Company Secretary is appointed, Sh. Rajiv Goyal, Chairman & Managing Director has been appointed as the Compliance Officer of the Company with effect from July 20, 2013 who shall liaison with the SEBI, Stock Ex

Surya Pharmaceutical Limited has submitted to the Exchange the Standalone Financial Results for the period ended March 31,2013.

Surya Pharmaceutical Limited has informed the Exchange regarding a Outcome of Board Meeting held on May 30, 2013.

Surya Pharmaceutical Limited has informed the Exchange that with reference to the earlier announcement with respect to approval of restructuring package by Corporate Debt Restructuring Empowered group (CDR-EG), the Company has now informed the Exchange that the master restructuring agreement (MRA) has been executed between the Company and lenders on March 31, 2013. The cut-off date for the CDR package is December 31, 2011. The CDR package envisages reduction in rate of Interest, deferment of payment of interest and principal amount of working capital facilities & term loans after a moratorium

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on February 14, 2013 has transacted the following: (1). Mr. Subhash Chander Marwaha has been appointed as Nominee Director-SBl w.e.f. January 23, 2013.(2). Further in continuation of the Company's previous communication with respect to decision of State Bank of India (the lead bank) for restructuring of the Company's debt, it is hereby informed that the Corporate Debt Restructuring empowered group(CDR-EG) has approved the restructuring package and taken on record in the Board o

Surya Pharmaceutical Limited has submitted to the Exchange the Standalone Financial Results along with the Limited Review Report for the period ended December 31,2012.

Surya Pharmaceutical Limited has submitted to the Exchange the Standalone Financial Results along with the Limited Review Report for the period ended September 30, 2012.

Surya Pharmaceutical Limited has submitted to the Exchange a copy of the Proceedings of the Annual General Meeting of the Company held on September 29, 2012.

Emm Bee Fincap Private Limited has submitted to the Exchange, vide letter dated September 21, 2012 a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Emm Bee Fincap Private Limited has submitted to the Exchange vide letter dated September 18, 2012, a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Emm Bee Fincap Private Limited has submitted to the Exchange vide letter dated September 14, 2012, a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Alka Goyal has submitted to the Exchange vide letter dated August 28, 2012 a copy of Disclosure in terms of Regulation 31(1) & 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Emm Bee Fincap Private Limited has submitted to the Exchange vide letter dated August 23, 2012, a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Alka Goyal has submitted to the Exchange vide its letter dated August 21, 2012 a copy of Disclosure in terms of Regulation 31(1) & 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Surya Pharmaceutical Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company shall remain closed from September 27, 2012 to September 29, 2012 for the purpose of Annual General Meeting to be held on September 29, 2012.

Alka Goyal has submitted to the Exchange vide its letter dated August 14, 2012 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Surya Pharmaceutical Limited has submitted to the Exchange the Standalone Financial Results for the period ended June 30,2012.

Alka Goyal has submitted to the Exchange, vide letter dated August 08, 2012 a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Alka Goyal has submitted to the Exchange, vide letter dated August 06, 2012 a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Alka Goyal has submitted to the Exchange, vide letter dated August 02, 2012 a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Alka Goyal has submitted to the Exchange, vide letter dated July 30, 2012 a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Alka Goyal has submitted to the Exchange, vide letter dated July 27, 2012 a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Alka Goyal has submitted to the Exchange, vide letter dated July 20, 2012 a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Alka Goyal has submitted to the Exchange, vide letter dated July 17, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Alka Goyal has submitted to the Exchange, vide letter dated July 16, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Alka Goyal has submitted to the Exchange, vide letter dated July 12, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Alka Goyal has submitted to the Exchange, vide letter dated July 10, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.